Pharma Business

  1. Home
  2. Pharma Business
  3. Core Technologies

In Vivo CAR-T

外泌體自體外給藥進入體內循環後，將奈米抗體CAR.BiTE基因遞送至T細胞，在體內完成免疫編程，訓練T細胞轉化為多靶向CAR-T細胞，再進入實體腫瘤內部毒殺癌細胞及瓦解腫瘤微環境
After exosomes are administered in vitro and enter the in vivo circulation, they deliver the nano-antibody CAR.BiTE gene to T cells, completing immune programming in vivo, training T cells to transform into multi-target CAR-T cells, and then entering solid tumors to kill cancer cells and disrupt the tumor microenvironment.
back